FDA Approves ConcizuTrace™ ELISA Companion Diagnostic for 2024 Concizumab Therapy in Hemophilia
The National Bleeding Disorders Foundation (NBDF) shared a post on X:
”The FDA has approved the ConcizuTrace™ ELISA Companion Diagnostic test to measure concizumab-mtci levels in hemophilia A and B patients.’
To learn more about this advancement, follow the link.
The U.S. Food and Drug Administration (FDA) has approved the ConcizuTrace™ ELISA Companion Diagnostic, a test designed to measure plasma levels of concizumab-mtci in patients with hemophilia A or B.
Concizumab-mtci is a subcutaneous therapy indicated for routine prophylaxis to prevent or reduce bleeding episodes in adult and pediatric patients (≥12 years) with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.
The approval of this companion diagnostic marks a significant step in personalizing treatment, enabling clinicians to monitor drug exposure and potentially optimize therapeutic outcomes.
Never miss the important in the World of Hemophilia, read Hemostasis Today.
-
Mar 6, 2026, 12:02Wolfgang Miesbach: Targeted Anti-TFPI Therapy with Marstacimab Supports Joint Stability in Hemophilia A
-
Mar 6, 2026, 11:49Love-Preet Kalra: Honored to Receive The Robert Wartenberg Award 2026
-
Mar 6, 2026, 11:43Matthew D. Neal: Turning Platelet Desert Into a Lifesaving Oasis at WTA 2026
-
Mar 6, 2026, 11:35Intensive Clotting Factor Prophylaxis Does Not Prevent Severe PPH in VWD – JTH
-
Mar 6, 2026, 09:15Reza Bavarsad Shahripour: When the Ophthalmic Artery Tells the Story of the Carotid
-
Mar 6, 2026, 09:13Louise St. Germain Bannon: Advancing Thrombosis and Hemostasis Through a Global Community
-
Mar 6, 2026, 09:06Kathleen Freson: Protein C Deficiency as a Genetic Modifier of Severe Haemophilia A
-
Mar 5, 2026, 17:48Estelle Carminita։ What If the Origin of Platelet Dysfunction Starts in the Bone Marrow
-
Mar 5, 2026, 17:43Pierre Sabouret: The Best Antithrombotic Strategy in Patients with Atherosclerotic Stroke and AF